GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş.

Investor Presentation • May 22, 2025

2025

K U L A

For Healthier GENerations

K U L A

For Healthier GENerations

K U L A Business

NPP Drugs

Drugs which prescribed by the doctors for the treatment of diseases and import permission is given by the Republic of Türkiye Ministry of Health but not registered in Türkiye and import can be imported trough Turkish Pharmacists Association (TEB), Türkiye Social Security Agency (SGK) and USHAŞ (Internations Health Services Inc.). Name of this import of drugs and delivery of the patients model is NPP (Named Patient Program) Drugs in this category and their producers represented in our country with exclusive distributorship agreement. Main difference between registered imported drugs and these drugs is sales of these drugs are not made in pharmaceutical warehouse but made in TEB, SGK and USHAŞ and sales price is determined in foreign currency

Registered Imported Drugs

Registered imported drugs are product portfolio which GEN has the rights of according to the exclusive distributorship agreement made with the foreign producer companies and these drugs are registered by the Republic of Türkiye Ministry of Health. Registrations are made for our company. All drugs within the scope of reimbursement. Registration is detailed process and rit may finalize up to 2 years after application. Sales prices of drugs in this determined by health authorities.

Branded Generic Drugs

In addition to original drugs, it has activities on development and sales of drugs which suitable for its portfolio and patent term expired.

Standards in High Inflation Economies has not been applied.

K U L A Drug

L A Drug Compared to the same period in 2024 39% increase 21/Q1 21/Q2 21/Q3 21/Q4 22/Q1 22/Q2 22/Q3 22/Q4 23/Q1 23/Q2 23/Q3 23/Q4 24/Q1 24/Q2 24/Q3 24/Q4 Activity Fields Exported Drug sales in the 1th quarter of 2025 Exported Drugs 34 27 37 95 57 81 80 26 96 60 45 120 209 127 92 182 In the first quarter of 2025, sales of Imported Imported 37% increase Registered Drugs 131 168 163 173 303 299 284 351 606 647 1.079 1.493 1.346 1.526 1.257 1.310 Registered Drugs compared to the same period of 2024 NPP 636 559 220 224 830 1.309 916 724 181 336 1.134 579 1.293 1.280 2.149 1.494 Compared to the same period of 2024 Üretim Ruhsatlı 9% increase İlaçlar 8 7 12 12 12 18 16 26 32 36 46 65 107 81 117 126 NPP Drug sales in the first quarter of 2025 Toplam 808 761 432 503 1.202 1707 1.296 1.127 915 1.079 2.304 2.257 2.955 3.014 3.615 3.112 Sales (TL) Distribution of Sales(%) 3.717.153.563 2025/Q1 2024/Q1 2023/Q1 Exported Drugs 8% Production Registered Drugs 2.452.293.394 1.852.395.497 1.411.000.702 1.292.821.895 NPP Drugs 915.492.439 843.137.654 38% Imported 605.509.072 290.797.246 208.808.901 181.168.786 162.960.118 107.524.944 Registered 96.314.144 32.500.437 Drugs N P P D R U G S I M P O R T E D P R O D U C T İ O N E X P O R T E D D R U G S T O T A L S A L E S *These values are calculated based on the invoice amounts for the products sold by the company, and R E G İ S T E R E D R E G İ S T E R E D TAS 29 Financial Reporting Standards in High Inflation Economies has not been applied. D R U G S D R U G S
												25/Q1 291
												1.852 1.411
												163 3.717

K U L A Drug

1.315.822

K U L A Export*

Compared to the same period of 2024 in the first quarter of 2025 to Azerbaijan Exports

75% increase

2025 yılı 1. Çeyreğinde 2024 yılının aynı dönemine göre

To Kazakhstan Exports

29% increase

İn the first quarter of 2025 in total Export volume

39% increase

Exports to 7 different countries

For Healthier GENerations * These values are calculated based on the invoice amounts for the products sold by the company, and TAS 29 Financial Reporting Standards in High Inflation Economies has not been applied.

Export by Country

Country	TL
Azerbaijan	176.485.025
Kazakhstan	70.663.244
Uzbekistan	5.882.799
Russia	35.951.233
Others**	1.814.945
Total	290.797.246

**Albania, Bosnia and Herzegovina, Philippines

K U L A Profitability

K U L A Profit Margins

K U L A Balance Sheet

Equities Current Ratio 1,38 8,3 Mr TL Financial Leverage* 0,22 x Assets 14+ Mr TL

**Total Financial Debts/Equities

For Healthier GENerations

Balance Sheet

Balance Sheet
TL	31.03.2025	31.12.2024
Total Current Assets	6.803.567.412	6.378.964.928
Total Fixed Assets	7.397.942.111	7.170.457.742
Total Assets	14.201.509.523	13.549.422.670
Total Short Term Liabilities	4.928.202.557	4.616.440.890
Total Long Term Liabilities	920.200.339	889.960.106
Total Liabilities	5.848.402.896	5.506.400.996
Total Current Assets	8.353.106.627	8.043.021.674
Current Raito	1,38	1,38

K U L A 2025 Expectations

K U L A
2025 Expectations
			Sales
	Price Determination Report	Planned
Sales	7.151.006.771	>TL 17,50 Bn
Gross Profit	1.470.704.605	>TL 4,20 Bn
Operating Profit	1.080.259.478	>TL 3,15 Bn
EBITDA	1.154.020.937	>TL 3,32 Bn	Operating Profit
Gross Profit Margin	20,56%	>24%
Operating Profit Margin	15,10%	>18%
EBITDA Margin	16,13%	>19%

For Healthier GENerations

K U L A 2025 Expectations

K U L A 2024 Realizations

	2025	Planned	Coverage Rate
Sales	3.857.985.687	>22.750.000.000	16,96%
Gross Profit	828.124.124	>5.340.000.000	15,50%
Operational Profit	531.560.104	>1.930.000.000	27,54%
EBITDA	358.991.527	>2.500.000.000	14,35%
Gross Profit Margin	21,47%	23,50%
Operating Profit Margin	13,78%	8,50%
EBITDA Margin	9,31%	11,00%

K U L A Income Statement

K U L A Growing

An exclusive distributorship agreement was signed with US-based IntraBio Inc. for the supply of the drug named

K U L A Research and Development

For Healthier GENerations

K U L A Drug

			2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025*	Toplam
In 2025/Q1:	Number of	Produced Drugs	8	1	18	2	9	17	30	24	18	16	1	144
	Registered Products	In Türkiye	6	1	7	0	2	1	4	6	0	3	0	30
2 new products in totally	2015-2025*	Abroad	2	0	11	2	7	16	26	18	18	13	1	114
6 products were licensed in		Exported Products	1	21	0	0	5	3	0	13	1	4	7	55
Türkiye.		In Türkiye	1	16	0	0	5	0	0	4	1	4	6	37
		Abroad	0	5	0	0	0	3	0	9	0	0	1	18
2 products		Total	9	22	18	2	14	20	30	37	19	20	8	199
were licensed in Georgia.		In Türkiye	7	17	7	0	7	1	4	10	1	7	6	67
		Abroad	2	5	11	2	7	19	26	27	18	13	2	132
	40 35 30 25 20 15 10 5 0	22 21 9 8 1 1 2015 2016	18 18 0 2017	2 2018	2 0	14 9 5 2019	17	20 3 2020	30 30 0 2021	24	37 13 2022	19 18 1 2023	16 2024	20 4
	* These are the datas includes	in 2025/Q1.			Produced Drugs			Exported Drugs	Total
For Healthier GENerations

K U L A Rare Solutions For Diseases Like SMA, MS

Solutions for Rare

With the partnerships made GEN ease access of patients to drugs for rare diseases within the scope of Named Patient Program (NPP). GEN has the leader position in this field.

Drug Research for NSCLC and other

Collaboration maintains with the RS Research which is established in Türkiye for the Non-Small Cell Lung Cancer

Alzheimer and other neurodegenerative illnesses

and other cancer types. Development of a new innovative drug for the Alzheimer and other neurodegenerative diseases with the collaboration made with Sulfateq B.V.

K U L A Strong

ELIXIR

95,00%

İlaç Araştırma ve Geliştirme A.Ş.

GEN's shareholding rate in Elixir, which is integrated into the GEN Production Campus, is

GENJECT Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş.

Genject, its own brand in Türkiye, manufactures single-use hypodermic syringes in accordance with CE standards. GEN's shareholding rate in GENJECT is

GEN Pharma Caucasus Manufacturing Operations MMC

GEN is a 66,00% shareholder of Gen Pharma Caucasus, which was established to establish a pharmaceutical production facility in Azerbaijan and to sell and market the products to be produced in this facility. Construction work of the facility is ongoing.

K U L A Innovative Investments in

K U L A

SUBSIDIARIES	ACTIVITY AND ESTABLISHMENT PLACE	MAIN ACTIVITY	SHARE RATIO (%)
	USA	Medical Device Development	19,30
	Türkiye	Drug Research and Development	11,70
	Switzerland	Drug and Food Supplement Research and Development	4,55
	Türkiye	Biotechnological Medical Device Research and Development	35,15
	Austria	Precision Cancer Immunotherapies	0,98
	Türkiye	Digtal Health Technologies	10,00
	USA	Drug Research and Development	6,70

K U L A Business Partners

K U L A Capacity

Semi-solid

Packaging

Sachet

K U L A

-

• 1,6 Mw Installed Solar Power %40-%45 of the Electricity Consumed by the Production Facility Comes from the Installed Solar Power Plant %56 Female Manager Rate %46 Female Employee Rate

-

We Are Not Different, We Are Aware - Employment of Individuals with Autism

• Compact
• Supporter of the 10 principles in the fields of Labor Standarts, Human Rights, Environment and Anti-Corruption 10 principles

K U L A Production

43.000 m2 Closed Area Europe, Türkiye, Russia, Kazakhstan, Philippines, Azerbaijan GMP approved.

1.200 m2 R&D Laboratory

Republic of Türkiye Minister of Science, Industry and Technology R&D Center Accreditation

For Healthier GENerations

K U L A Stock

29.03.2024 Price	TL 65,80
28.03.2025 Price	TL 135,65
28.03.2025 Market Size TL	TL 40,69 Bn / USD1,07 Bn

K U L A Innovative

		RS-139
		Solid Cancers
Phase 1 is ongoing.	Phase 2 completed. Phase 3 will be launched in 2026	Phase 1b is ongoing.
15%	80%	4%
6 yıl (2031 license application)	2 years (2028 license application)	8 years (2033 license application)
An estimated 600 thousand patients in Türkiye.	An estimated 1.5 million patients in Türkiye.	It depends on Indication
	USD 150 Mn	It depends on Indication
USD 12 Mn		It depends on Indication
USD 5,2 Bn¹	USD 20 Bn²
55%	85%	45%
Amfoterisin B	Metoxalen
	SUL-238 Alzheimer's and Neurodegenerative diseases	GN-037 Psoriasis (Psoriasis Vulgaris)

Project Name	SUL-238		GN-037
Indication		Alzheimer's and Neurodegenerative diseases	Psoriasis (Psoriasis Vulgaris)
			Phase 2 completed. Phase 3 will be launched in 2026	Phase 1b is ongoing.
The Probability of the Project Being Released, at this Stage (%)	15%		80%
			2 years (2028 license application)
Estimated Number of Patients in Türkiye		An estimated 600 thousand patients in Türkiye.	An estimated 1.5 million patients in Türkiye.
			USD 150 Mn
			USD 20 Bn²
Project Completion Rate (%)	55%		85%
Project Name		Amfoterisin B	Metoxalen
Indication		Sistemik mantar enfeksiyonları	Sedef hastalığı (plak psoriasis)+PUVA
Stage		Generic of the original Ambisome product.	Generic of the original Oxsoralen Ultra product.
The Probability of the Project Being Released, at this Stage (%)		95%	80%
Time Required for Commercialization Under the	Best Case	2 years (2027 license application)	3 years (2027 license application)
The Estimated Number of Patients in Türkiye		It depends on Indication	An estimated 1.5 million patients in Türkiye.
2024 Türkiye Market Share Size \$ 2024 Global Market Share Size \$		USD 20 Mn USD 1.2 Bn ³	USD 150 Mn USD 20 Bn⁴

(²) https://www.globenewswire.com/news-release/2025/01/23/3014054/28124/en/Plaque-Psoriasis-Market-Research-2024-2034-Environmental-and-Genetic-Factors-Boost-Demand-Investments-in-Medical-R-D-Catalyze-Innovations.html (³) https://dataintelo.com/report/global-liposomal-amphoteracin-b-market

(⁴) https://www.globenewswire.com/news-release/2025/01/23/3014054/28124/en/Plaque-Psoriasis-Market-Research-2024-2034-Environmental-and-Genetic-Factors-Boost-Demand-Investments-in-Medical-R-D-Catalyze-Innovations.html

K U L A

K U L A Summary

K U L A
Summary
	31.03.2025	31.12.2024		31.03.2025	31.12.2024
ASSEST			Short Term Liabilities Short Term Debts	1.172.997.725	436.419.091
Current Assets			Short Term Portion of Long-Term Financial Debts	334.773.082	348.356.465
Cash and Cash Equivalents	313.947.216	597.612.034	Trade Payables
Financial Assets	99.087.649	101.834.785	- Trade Payables, Related Parties	--	12.693.260
Trade Receivables			- Trade Payables, Third Parties	2.568.603.646	2.948.953.080
- Trade Receivables, Related Parties	392.354.908	327.111.220	Employee Benefit Obligations	60.244.326	23.928.775
- Trade Receivables, Third Parties	1.660.831.332	1.473.819.599	Other Payables
			- Other Patables, Related Parties	6.217.477	7.019.736
Other Receivables			- Other Payables, Third Parties	36.543.362	21.508.750
- Other Receivables, Related Parties	1.343.625.005	641.886.383	Deferred Incomes	658.992.761	777.447.163
- Other Payables, Third Parties	7.095.448	9.073.525	Current Income Tax Liabiliteis Short Term Provissions	29.900.229	2.271.950
Stocks	1.414.276.529	1.180.377.609
Prepaid Expenses	1.467.752.668	1.969.831.690	- Short Term Provissions for Employee Benefits	51.687.847	28.771.136
Current Tax-Related Assets	19.554.416	20.884.391	- Other Short Term Provissions	8.242.102	9.071.484
Other Current Assets Total Current Assets	85.042.241 6.803.567.412	56.533.692 6.378.964.928	Total Short Term Liabilities	4.928.202.557	4.616.440.890
			Long Term Liabilities
Non-Current Assets			Long Term Financial Liabilities	401.771.054	478.028.921
Financial Assets	872.229.249	774.706.433	Trade Payables - Other Payables, Third Parties	10.364.683	12.850.896
Investment Properties	620.301.643	620.301.643	Deferred Incomes	--	289.775
Intangible Non-Current Assets	4.533.823.068	4.531.299.912	Long Term Provissions
Intangible Assets	1.111.701.944	1.060.390.315
Prepaid Expenses	246.881.564	164.039.861	- Long Term Provissions for Employee Benefits	85.514.411	82.800.492
Deferred Tax Assets	13.004.643	19.719.578	Deferred Tax Liabilities	422.550.191	315.990.022
Total Non-Current Assets	7.397.942.111	7.170.457.742	Total Long Term Liabilities	920.200.339	889.960.106
Total Assets	14.201.509.523	13.549.422.670	Total Liabilities
				5.848.402.896	5.506.400.996

K U L A Equities

	31.03.2025	31.12.2024
EQUITIES
Equity Attributable to Owners of the Parent
Share Capital	300.000.000	300.000.000
Adjustment to Share Capital	1.172.997.725	436.419.091
Buyback Shares	-34.357.992	-34.357.992
Share Premiums/Discounts	2.485.088.479	2.485.088.479
Other Comprehensive Income/Expense not to be Reclassified to profit
- Actuarial Loss / Gain	-91.552.017	-85.990.551
- Revaluation and Reclassification Gains	1.337.770.684	1.337.770.684
Comprehensive Income or Expenses
- Foreign Currency Conversion Difference	-460.870	225.304
Restricted Reserves Allocated from Profit	416.850.838	416.850.838
Prior Years Profit	1.892.108.812	1.728.461.413
Net Profit for the Period	319.818.134	163.637.808
Non Controlling Shares	-1.967.385	1.527.747
Total Equity	8.353.106.627	8.043.021.674
TOTAL ASSETS	14.201.509.523	13.549.422.670

K U L A Summary

	1 January –	1 January –
	31 March 2025	31 March 2024
Revenue Cost of Sales (-)	3.857.985.687 -3.029.861.563	4.280.375.784 -3.408.950.307
Gross Profit General Administrative Expenses (-)	828.124.124 -196.422.309	871.425.477 -148.053.362
Marketing, Selling and Distribution Expenses (-)	-387.914.495	-326.218.236
Other Operating Income	614.656.725	237.814.399
Other Operating Expenses (-)	-326.883.941	-208.031.763
Operating Profit	531.560.104	426.936.515
Income from Investing Activities	9.390.601	52.504.644
Expenses from Investing Activities (-)	-7.900.718	--
Operating Profit / (Loss) Before Financial Income	533.049.987	479.441.159
Financial Income	33.331.351	89.837.766
Financial Expenses (-)	-185.084.828	-242.922.861
Monetary Loss / Gain	75.011.503	-6.919.908
Profit Before Tax	456.308.013	319.436.156
- Tax for the Period	-27.812.910	-22.198.308
- Deferred Tax Income	-112.162.884	-86.603.753
PROFIT FOR THE PERIOD	316.332.219	210.634.095
Profit for the period Attributable to
Non Controlling Shares	-3.485.915	-12.668.494
Equity Holders for the Parent	319.818.134	223.302.587
PROFIT FOR THE PERIOD	316.332.219	210.634.093
Earning Per Share	1,05	0,70

K U L A Investor Relations

yatirimciiliskileri@genilac.com

https://www.genilac.com.tr/yatirimci-iliskileri-gen

Investor Relations Specialist

K U L A

All information presented in this presentation (presentation) has been prepared by Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GENIL) in order to present information, projection and expressions about GENIL. The accuracy, adequacy and completeness of the information in this Presentation is not warrented. GENIL assumes no liability for any consequences arising from the use or content of this Presentation. This Presentation is subject to change without notice, does not contain any investment advice or constitutes an offer or invitation to sell GENIL shares. This presentation and/or all information contained in the Presentation cannot be coppied, disclosed or distrubuted to any person unless shared or send by GENIL to relevant person.

All information in this presentation is top secret, the forward-looking statement contained in the Presentation is mentioned only as of the date of Presentation This presentation contains some forward-looking views and estimated figures. These reflect the current views of the Company Management regarding the future situation and include certain assumptions. However the realizations, may differ depending on the developments and realizations in the variables and assumptions that make up the forward-looking views and estimated figures. GENIL, or it employees, board of directors members, managers are not responsible from the losses arising from usage of the content of this Presentation.

For Healthier GENerations Thank You.

K U L A